Organic Active Ingredients TRIZ Cases

Small-molecule quinolinone amides target cardiac myosin to improve ventricular relaxation and reduce invasive HCM treatment risks.

Surface stimulation at multiple spinal levels activates locomotor circuits to restore stepping, standing, grasping, and autonomic function after injury.

Suspending agents, surfactants, and sweeteners balance stability, dosing uniformity, and taste in a pediatric-friendly tasimelteon liquid.

Blocking 15-PGDH slows PGE2 breakdown, extending neuroprotective signaling to support neuronal survival and regeneration after injury.

Selective ROCK2 inhibition targets viral pathways while reducing fibrosis, inflammation, and cytokine storm after coronavirus infection.

A biomarker signature using phosphorylated protein thresholds separates likely responders to ATR/CHK1 pathway inhibitors from non-responders.

Structural tuning of ionizable cationic lipids improves nucleic acid encapsulation and transfection while reducing cytotoxicity.

Casimersen drives exon 45 skipping to restore the mRNA reading frame, increase dystrophin, and avoid glucocorticoid side effects in DMD.

Biodegradable AKG-PEG microparticles enable sustained local release to promote bone regeneration while avoiding high-dose BMP2 side effects.

Transient VLP delivery of Cas9:gRNA RNP knocks out mutant HTT without genome integration, lowering off-target and long-term safety risks.

A non-phospholipid surfactant and propylene glycol keep nimodipine soluble during moist heat sterilization while reducing irritation and impurities.

Abatacept blocks T-cell co-stimulation to treat steroid-resistant checkpoint inhibitor adverse events such as myocarditis, myositis, and hepatitis.

A potent low-dose CETP inhibitor achieves near-complete inhibition while reducing tablet burden, side effects, and pharmacokinetic variability.

A low-dose, pH-buffered diaminophenothiazine formulation uses sustained release to protect corneal nerves while reducing ocular toxicity and staining.

ORL-1 receptor modulators improve sleep efficiency and latency while reducing side effects and addiction risk in sleep disorder treatment.

Micropost mixing and flow control tune molar ratios and Reynolds number to produce uniform lipid nanoparticles with strong nucleic acid encapsulation.

A plant-derived catechin apiofuranoside inhibits DHT formation and oxidative stress apoptosis in dermal papilla cells for alopecia care.

Amorphous enzalutamide in an HPMCAS solid dispersion improves solubility, dissolution stability, and oral absorption for single-tablet dosing.

A tert-butanol/water TH-302 lyophilized formulation raises drug loading, cuts vial count, and avoids adverse reactions from dimethylacetamide.

Biodegradable cationic and PEG lipids shield nucleic acids from plasma degradation while enabling intracellular delivery with lower toxicity.

Site-specific anti-Nectin-4 MMAE formulation uses histidine buffer, trehalose, surfactant, and lyophilization to limit shedding and aggregation.

A small-molecule composition boosts p62 S403 phosphorylation to enhance aggrephagy and clear protein aggregates in neurodegenerative disease.

Targeting the HSPB8 3' UTR with RNAi oligonucleotides suppresses mutant-linked expression and helps restore mitochondrial morphology.

Sequence-specific oligonucleotides suppress REST expression while balancing therapeutic efficacy with off-target risk in neurological disease treatment.

Flavonoids added to steviol glycoside and mogroside sweeteners boost sweetness and suppress bitterness for a more sucrose-like taste.

A mild solvent and surfactant system improves retinol stability and skin delivery while reducing irritation in topical treatment.

Controlled mirabegron particle size and high-molecular-weight polyethylene oxide improve dissolution, homogeneity, and stability in modified-release tablets.

Two biocompatible polymers form a self-healing hydrogel with prolonged mucosal retention, avoiding harsh polymer modification steps.

A palatable supplement blend buffers gastric acidity and helps prevent or treat equine ulcers without the side effects of existing feeds.

Targeting mGluR5 with mavoglurant helps reduce cocaine use, prevent relapse, and improve abstinence retention with fewer off-target limits.

Novel dihydrothienopyrimidine derivatives selectively inhibit PDE4B to suppress inflammation and fibrosis while maintaining low toxicity.

A novel 99mTc-FAPI dimer scaffold boosts tumor uptake and imaging contrast while reducing non-target organ uptake in SPECT tumor diagnosis.

A functional chelate linker with PEI, PEG, or cathepsin B binding improves intracellular retention of radiometal-labeled antibodies for therapy.

Nine methanesulfonate crystal forms improve solubility and stability, enabling scalable preparation and storage of C-Met/HGFR cancer therapies.

Blocking CD38 prevents NAD+ breakdown, helping raise intracellular NAD+ levels for mitochondrial and metabolic disease treatment.

Selective TYK2 JH2-binding carboxamides inhibit IL-23 and IFNα signaling to treat autoimmune disease with fewer side effects.

Selective oxathiazin-like compounds reduce broad cytokine release in CRS while preserving cancer immunotherapy effectiveness.

Prodrug conversion slows release of the NMDA antagonist after dosing, lowering IV misuse and overdose risk while preserving efficacy.

Early idebenone treatment helps preserve respiratory function in viral ARDS while reducing bronchopulmonary complications and antibiotic need.

Serotonin agonists and SSRIs shift spore-forming gut bacteria colonization to regulate lipid and steroid metabolism and lower triglycerides.

A GABA, arginine, and niacin composition improves sleep quality and stress relief while limiting next-day drowsiness.

Topical AhR agonist derivatives improve solubility and dissolution to raise bioavailability while limiting systemic exposure and adverse events.

An injectable alginate gel confines radionuclides in tumors and uses catalase-generated oxygen to overcome hypoxia and improve radiation killing.

Lipase-coated particles hydrolyze triglycerides before enteral delivery, improving LC-PUFA absorption without porcine enzyme exposure.

Measuring CD19 exon2del transcripts helps predict resistance to CD19 immunotherapy and guides alternative treatment selection.

A layered bioerodible implant uses permeable and impermeable polymers to maintain constant drug release and avoid removal after dosing.

Specific scaffold and linker sequences let one vector express multiple shRNAs while limiting recombination and off-target gene silencing.

Male- and female-sourced amniotic fluid enables more specific treatment of tissue disease and improves consistency in erectile dysfunction and Peyronie's care.

Converting a poorly soluble Nox1/Nox4 inhibitor into an ionic liquid improves aqueous solubility, bioavailability, and neuroprotection in Parkinson's disease.

Selective tricyclic JAK1 inhibitors improve potency against inflammatory disease and cancer while reducing off-target kinase effects.